But we also cannot lose sight of the ways that drug companies continue to abuse our intellectual property laws to drive out competition, to jack up prices, and to protect their profits.
Elizabeth Warren
The Public Record
Elizabeth Ann Warren is an American attorney, academic, and politician serving as the senior United States senator from Massachusetts since 2013. A member of the Democratic Party, she has been a prominent advocate for consumer protection, economic equality, and corporate regulation. Warren gained national recognition for her work in establishing the Consumer Financial Protection Bureau and has focused on issues such as student debt relief and healthcare reform during her tenure in the Senate.
Despite these wins, there is more that we need to do to reduce exorbitant drug prices for all Americans.
But we also cannot lose sight of the ways that drug companies continue to abuse our intellectual property laws to drive out competition, to jack up prices, and to protect their profits.
Wow. Well, you know, we must ensure that drug companies do not rely on tricks in order to avoid competition.
So last year, Congress passed the Inflation Reduction Act, which finally gives HHS the authority to negotiate drug prices for a select number of high-priced brand-name drugs.
Okay. So drug companies use these tricks, and a lot of others, to keep their monopolies and keep pushing prices higher and higher and higher.
Wow. Well, you know, we must ensure that drug companies do not rely on tricks in order to avoid competition.
So, think about that. More than three out of four new patent applications for pharmaceuticals are for existing drugs.
Okay. So drug companies use these tricks, and a lot of others, to keep their monopolies and keep pushing prices higher and higher and higher.
So last year, Congress passed the Inflation Reduction Act, which finally gives HHS the authority to negotiate drug prices for a select number of high-priced brand-name drugs.
Wow. Well, you know, we must ensure that drug companies do not rely on tricks in order to avoid competition.
But we also cannot lose sight of the ways that drug companies continue to abuse our intellectual property laws to drive out competition.
It seems to me the solution is clear. It is time to expand Medicare to cover dental care, something I have long supported.
Since Medicare was established in 1965, it has not covered routine dental benefits.
CMS should absolutely finalize this rule. But I want to argue here that CMS needs to go further and end these insurance industry scams.
Since Medicare was established in 1965, it has not covered routine dental benefits.
It seems to me the solution is clear. It is time to expand Medicare to cover dental care, something I have long supported.
CMS should absolutely finalize this rule. But I want to argue here that CMS needs to go further and end these insurance industry scams.
Or we can spend nearly a trillion dollars in overpayments to insurance companies for crummy coverage that beneficiaries do not use.
The name of the game is volume. The more volume a drug company has with a particular PBM, and the greater the drug company's market share, the better the potential deal that the drug company can offer as an inducement to disfavor rival…
So drug companies use these tricks, and a lot of others, to keep their monopolies and keep pushing prices higher and higher and higher.
Despite these wins, there is more that we need to do to reduce exorbitant drug prices for all Americans.
Or we can spend nearly a trillion dollars in overpayments to insurance companies for crummy coverage that beneficiaries do not use.
So last year, Congress passed the Inflation Reduction Act, which finally gives HHS the authority to negotiate drug prices for a select number of high-priced brand-name drugs.
More than three out of four new patent applications for pharmaceuticals are for existing drugs.





